Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.

van Dijk AD, de Bont ESJM, Kornblau SM.

Expert Rev Proteomics. 2020 Jan 16. doi: 10.1080/14789450.2020.1717951. [Epub ahead of print]

PMID:
31945303
2.

Social competence in newly diagnosed pediatric brain tumor patients.

Kok TB, Koerts J, Lemiere J, Post WJ, de Bont ESJM, Gidding C, Happé F, Jacobs S, Oostrom K, Schieving J, Tucha O, Kingma A.

Pediatr Hematol Oncol. 2020 Feb;37(1):41-57. doi: 10.1080/08880018.2019.1682089. Epub 2019 Nov 4.

PMID:
31682775
3.

Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair.

Mahmud H, Ter Elst A, Scherpen FJG, Boer TM, Kampen KR, de Haas V, Guryev V, Peppelenbosch MM, Kornblau SM, de Bont ESJM.

Oncotarget. 2019 Jul 23;10(45):4679-4690. doi: 10.18632/oncotarget.27086. eCollection 2019 Jul 23.

4.

Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study.

de Bruijn CMA, Millot F, Suttorp M, Borisevich M, Brons P, Lausen B, de Bont ESJM.

Br J Haematol. 2019 May;185(4):718-724. doi: 10.1111/bjh.15826. Epub 2019 Mar 6.

PMID:
30843196
5.

Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse.

Hoff FW, Hu CW, Qutub AA, Qiu Y, Hornbaker MJ, Bueso-Ramos C, Abbas HA, Post SM, de Bont ESJM, Kornblau SM.

Proteomics Clin Appl. 2019 Jul;13(4):e1800133. doi: 10.1002/prca.201800133. Epub 2019 Feb 4.

6.

Lysosomal Signaling Licenses Embryonic Stem Cell Differentiation via Inactivation of Tfe3.

Villegas F, Lehalle D, Mayer D, Rittirsch M, Stadler MB, Zinner M, Olivieri D, Vabres P, Duplomb-Jego L, De Bont ESJM, Duffourd Y, Duijkers F, Avila M, Geneviève D, Houcinat N, Jouan T, Kuentz P, Lichtenbelt KD, Thauvin-Robinet C, St-Onge J, Thevenon J, van Gassen KLI, van Haelst M, van Koningsbruggen S, Hess D, Smallwood SA, Rivière JB, Faivre L, Betschinger J.

Cell Stem Cell. 2019 Feb 7;24(2):257-270.e8. doi: 10.1016/j.stem.2018.11.021. Epub 2018 Dec 27.

PMID:
30595499
7.

Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO-DBH-AML study.

Bager N, Juul-Dam KL, Sandahl JD, Abrahamsson J, Beverloo B, de Bont ESJM, Ha SY, Jahnukainen K, Jónsson ÓG, Kaspers GL, Kovalova Z, Lausen B, De Moerloose B, Noren-Nyström U, Palle J, Saks K, Zeller B, Kjeldsen E, Hasle H.

Br J Haematol. 2018 Nov;183(4):618-628. doi: 10.1111/bjh.15587. Epub 2018 Nov 8.

PMID:
30406946
8.

Mycoplasma contamination of leukemic cell lines alters protein expression determined by reverse phase protein arrays.

Hoff FW, Hu CW, Qutub AA, Qiu Y, Graver E, Hoang G, Chauhan M, de Bont ESJM, Kornblau SM.

Cytotechnology. 2018 Dec;70(6):1529-1535. doi: 10.1007/s10616-018-0244-2. Epub 2018 Sep 6.

9.

VEGFC Antibody Therapy Drives Differentiation of AML.

Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ESJM.

Cancer Res. 2018 Oct 15;78(20):5940-5948. doi: 10.1158/0008-5472.CAN-18-0250. Epub 2018 Sep 5.

10.

Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.

Suttorp M, Schulze P, Glauche I, Göhring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C.

Leukemia. 2018 Jul;32(7):1657-1669. doi: 10.1038/s41375-018-0179-9. Epub 2018 Jun 20.

PMID:
29925908
11.

Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic.

Hoff FW, Hu CW, Qutub AA, de Bont ESJM, Horton TM, Kornblau SM.

Expert Rev Proteomics. 2018 Jul;15(7):613-622. doi: 10.1080/14789450.2018.1487781. Epub 2018 Jul 6. Review.

12.

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.

van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, De Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM.

Haematologica. 2018 Sep;103(9):1484-1492. doi: 10.3324/haematol.2017.187153. Epub 2018 May 17.

13.

An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.

Kaspers GJL, Niewerth D, Wilhelm BAJ, Scholte-van Houtem P, Lopez-Yurda M, Berkhof J, Cloos J, de Haas V, Mathôt RA, Attarbaschi A, Baruchel A, de Bont ES, Fagioli F, Rössig C, Klingebiel T, De Moerloose B, Nelken B, Palumbo G, Reinhardt D, Rohrlich PS, Simon P, von Stackelberg A, Zwaan CM.

Br J Haematol. 2018 May;181(4):523-527. doi: 10.1111/bjh.15233. Epub 2018 Apr 20.

PMID:
29676440
14.

Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance.

Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Scheurer ME, de Bont ESJM, Qutub AA, Kornblau SM, Horton TM.

Mol Cancer Res. 2018 Aug;16(8):1263-1274. doi: 10.1158/1541-7786.MCR-17-0730. Epub 2018 Apr 18.

15.

Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets.

Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Mahmud H, de Bont ESJM, Qutub AA, Horton TM, Kornblau SM.

Mol Cancer Res. 2018 Aug;16(8):1275-1286. doi: 10.1158/1541-7786.MCR-17-0731. Epub 2018 Apr 18.

16.

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.

Cucchi DGJ, Denys B, Kaspers GJL, Janssen JJWM, Ossenkoppele GJ, de Haas V, Zwaan CM, van den Heuvel-Eibrink MM, Philippé J, Csikós T, Kwidama Z, de Moerloose B, de Bont ESJM, Lissenberg-Witte BI, Zweegman S, Verwer F, Vandepoele K, Schuurhuis GJ, Sonneveld E, Cloos J.

Blood. 2018 May 31;131(22):2485-2489. doi: 10.1182/blood-2017-12-819508. Epub 2018 Apr 18.

PMID:
29669779
17.

Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma.

Zomerman WW, Plasschaert SLA, Conroy S, Scherpen FJ, Meeuwsen-de Boer TGJ, Lourens HJ, Guerrero Llobet S, Smit MJ, Slagter-Menkema L, Seitz A, Gidding CEM, Hulleman E, Wesseling P, Meijer L, van Kempen LC, van den Berg A, Warmerdam DO, Kruyt FAE, Foijer F, van Vugt MATM, den Dunnen WFA, Hoving EW, Guryev V, de Bont ESJM, Bruggeman SWM.

Cell Rep. 2018 Mar 20;22(12):3206-3216. doi: 10.1016/j.celrep.2018.02.089.

18.

Histone Modification Patterns Using RPPA-Based Profiling Predict Outcome in Acute Myeloid Leukemia Patients.

van Dijk AD, Hu CW, de Bont ESJM, Qiu Y, Hoff FW, Yoo SY, Coombes KR, Qutub AA, Kornblau SM.

Proteomics. 2018 Apr;18(8):e1700379. doi: 10.1002/pmic.201700379. Epub 2018 Apr 2.

PMID:
29505696
19.

High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer.

Diets IJ, Waanders E, Ligtenberg MJ, van Bladel DAG, Kamping EJ, Hoogerbrugge PM, Hopman S, Olderode-Berends MJ, Gerkes EH, Koolen DA, Marcelis C, Santen GW, van Belzen MJ, Mordaunt D, McGregor L, Thompson E, Kattamis A, Pastorczak A, Mlynarski W, Ilencikova D, van Silfhout AV, Gardeitchik T, de Bont ES, Loeffen J, Wagner A, Mensenkamp AR, Kuiper RP, Hoogerbrugge N, Jongmans MC.

Clin Cancer Res. 2018 Apr 1;24(7):1594-1603. doi: 10.1158/1078-0432.CCR-17-1725. Epub 2018 Jan 19.

20.

Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients.

Hanekamp D, Denys B, Kaspers GJL, Te Marvelde JG, Schuurhuis GJ, De Haas V, De Moerloose B, de Bont ES, Zwaan CM, de Jong A, Depreter B, Lammens T, Philippé J, Cloos J, van der Velden VHJ.

Br J Haematol. 2018 Nov;183(3):512-516. doi: 10.1111/bjh.14991. Epub 2017 Oct 26. No abstract available.

PMID:
29076143
21.

Peptide microarray profiling identifies phospholipase C gamma 1 (PLC-γ1) as a potential target for t(8;21) AML.

Mahmud H, Scherpen FJG, de Boer TM, Lourens HJ, Schoenherr C, Eder M, Scherr M, Guryev V, De Bont ES.

Oncotarget. 2017 Jun 27;8(40):67344-67354. doi: 10.18632/oncotarget.18631. eCollection 2017 Sep 15.

22.

Optimizing VAP scars after childhood cancer treatment: a pilot study.

de Bruijn CMA, Hoff FW, Bruggeman-Westermann MM, Terra JB, van Dijk TH, de Bont ESJM, Peek AML.

Support Care Cancer. 2017 Dec;25(12):3651-3654. doi: 10.1007/s00520-017-3787-4. Epub 2017 Jun 28.

23.

Validation of a clinical screening instrument for tumour predisposition syndromes in patients with childhood cancer (TuPS): protocol for a prospective, observational, multicentre study.

Postema FA, Hopman SM, de Borgie CA, Hammond P, Hennekam RC, Merks JH; TuPS study group, Aalfs CM, Anninga JK, Berger LP, Bleeker FE, de Bont ES, de Borgie CA, Dommering CJ, van Eijkelenburg NK, Hammond P, Hennekam RC, van den Heuvel-Eibrink MM, Hopman SM, Jongmans MC, Kors WA, Letteboer TG, Loeffen JL, Merks JH, Olderode-Berends MJ, Postema FA, Wagner A; TuPS study group.

BMJ Open. 2017 Jan 20;7(1):e013237. doi: 10.1136/bmjopen-2016-013237.

24.

Feasibility of video consultations in case of acute complications in children with haemophilia.

Ludikhuize L, Jansen ME, Hooimeijer HL, de Bont ES, Tamminga RY.

Haemophilia. 2016 Nov;22(6):e567-e570. doi: 10.1111/hae.13109. Epub 2016 Oct 20. No abstract available.

PMID:
27761970
25.

Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia.

Mahmud H, Kornblau SM, Ter Elst A, Scherpen FJ, Qiu YH, Coombes KR, de Bont ES.

J Hematol Oncol. 2016 Aug 3;9(1):64. doi: 10.1186/s13045-016-0294-x.

26.

Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas.

Helfferich J, Nijmeijer R, Brouwer OF, Boon M, Fock A, Hoving EW, Meijer L, den Dunnen WF, de Bont ES.

Crit Rev Oncol Hematol. 2016 Aug;104:30-41. doi: 10.1016/j.critrevonc.2016.05.008. Epub 2016 May 21. Review.

27.

Single-cell sequencing reveals karyotype heterogeneity in murine and human malignancies.

Bakker B, Taudt A, Belderbos ME, Porubsky D, Spierings DC, de Jong TV, Halsema N, Kazemier HG, Hoekstra-Wakker K, Bradley A, de Bont ES, van den Berg A, Guryev V, Lansdorp PM, Colomé-Tatché M, Foijer F.

Genome Biol. 2016 May 31;17(1):115. doi: 10.1186/s13059-016-0971-7.

28.

Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.

Vos HI, Guchelaar HJ, Gelderblom H, de Bont ES, Kremer LC, Naber AM, Hakobjan MH, van der Graaf WT, Coenen MJ, te Loo DM.

Pharmacogenet Genomics. 2016 May;26(5):243-7. doi: 10.1097/FPC.0000000000000212.

PMID:
26928270
29.

Very early discharge versus early discharge versus non-early discharge in children with cancer and febrile neutropenia.

Loeffen EA, Te Poele EM, Tissing WJ, Boezen HM, de Bont ES.

Cochrane Database Syst Rev. 2016 Feb 22;2:CD008382. doi: 10.1002/14651858.CD008382.pub2. Review.

PMID:
26899263
30.

Risk-adapted approach for fever and neutropenia in paediatric cancer patients--a national multicentre study.

Miedema KG, Tissing WJ, Abbink FC, Ball LM, Michiels EM, van Vliet MJ, de Vries WY, Kamps WA, Norbruis OF, Fiocco M, de Groot-Kruseman HA, van de Wetering MD, de Bont ES.

Eur J Cancer. 2016 Jan;53:16-24. doi: 10.1016/j.ejca.2015.10.065. Epub 2015 Dec 14.

PMID:
26700076
31.

Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines.

Zomerman WW, Plasschaert SL, Diks SH, Lourens HJ, Meeuwsen-de Boer T, Hoving EW, den Dunnen WF, de Bont ES.

PLoS One. 2015 Oct 23;10(10):e0141381. doi: 10.1371/journal.pone.0141381. eCollection 2015.

32.

Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?

van der Sligte NE, Kampen KR, de Bont ES.

Cell Mol Life Sci. 2015 Oct;72(19):3589-98. doi: 10.1007/s00018-015-2019-7. Epub 2015 Aug 31.

33.

Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B, Dworzak M, Gibson BE, Hasle H, Leverger G, Locatelli F, Ragu C, Ribeiro RC, Rizzari C, Rubnitz JE, Smith OP, Sung L, Tomizawa D, van den Heuvel-Eibrink MM, Creutzig U, Kaspers GJ.

J Clin Oncol. 2015 Sep 20;33(27):2949-62. doi: 10.1200/JCO.2015.62.8289. Epub 2015 Aug 24. Review.

34.

Sharing decisions during diagnostic consultations; an observational study in pediatric oncology.

Wiering BM, Noordman J, Tates K, Zwaanswijk M, Elwyn G, De Bont ES, Beishuizen A, Hoogerbrugge PM, Van Dulmen S.

Patient Educ Couns. 2016 Jan;99(1):61-7. doi: 10.1016/j.pec.2015.07.026. Epub 2015 Jul 29.

PMID:
26298218
35.

Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

van der Sligte NE, Scherpen FJ, Ter Elst A, Guryev V, van Leeuwen FN, de Bont ES.

Exp Hematol Oncol. 2015 Aug 12;4:23. doi: 10.1186/s40164-015-0017-y. eCollection 2015.

36.

Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia.

van der Sligte NE, Kampen KR, ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Guryev V, van Leeuwen FN, Kornblau SM, de Bont ES.

Oncotarget. 2015 Jun 20;6(17):14970-81.

37.

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES.

Mol Cancer Res. 2015 Jun;13(6):982-92. doi: 10.1158/1541-7786.MCR-14-0660-T. Epub 2015 May 5.

38.

Gene expression profiles associated with pediatric relapsed AML.

Bachas C, Schuurhuis GJ, Zwaan CM, van den Heuvel-Eibrink MM, den Boer ML, de Bont ES, Kwidama ZJ, Reinhardt D, Creutzig U, de Haas V, Kaspers GJ, Cloos J.

PLoS One. 2015 Apr 7;10(4):e0121730. doi: 10.1371/journal.pone.0121730. eCollection 2015.

39.

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.

Hagleitner MM, Coenen MJ, Gelderblom H, Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HW, Flucke U, van Leeuwen FN, Hoogerbrugge PM, Guchelaar HJ, te Loo DM.

Clin Cancer Res. 2015 Aug 1;21(15):3436-41. doi: 10.1158/1078-0432.CCR-14-2638. Epub 2015 Mar 31.

40.

Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.

Sie M, den Dunnen WF, Lourens HJ, Meeuwsen-de Boer TG, Scherpen FJ, Zomerman WW, Kampen KR, Hoving EW, de Bont ES.

PLoS One. 2015 Mar 23;10(3):e0122555. doi: 10.1371/journal.pone.0122555. eCollection 2015.

41.

Malnutrition is associated with worse health-related quality of life in children with cancer.

Brinksma A, Sanderman R, Roodbol PF, Sulkers E, Burgerhof JG, de Bont ES, Tissing WJ.

Support Care Cancer. 2015 Oct;23(10):3043-52. doi: 10.1007/s00520-015-2674-0. Epub 2015 Mar 10.

42.

Weight and height in children newly diagnosed with cancer.

Brinksma A, Roodbol PF, Sulkers E, Hooimeijer HL, Sauer PJ, van Sonderen E, de Bont ES, Tissing WJ.

Pediatr Blood Cancer. 2015 Feb;62(2):269-273. doi: 10.1002/pbc.25301. Epub 2014 Oct 30. Review.

PMID:
25359660
43.

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.

Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, van Leeuwen FN, Gelderblom H, Hoogerbrugge PM, Guchelaar HJ, Te Loo MW.

PLoS One. 2014 Dec 31;9(12):e115869. doi: 10.1371/journal.pone.0115869. eCollection 2014.

44.

Kinase activity profiling reveals active signal transduction pathways in pediatric acute lymphoblastic leukemia: a new approach for target discovery.

van der Sligte NE, Scherpen FJ, Meeuwsen-de Boer TG, Lourens HJ, Ter Elst A, Diks SH, Guryev V, Peppelenbosch MP, van Leeuwen FN, de Bont ES.

Proteomics. 2015 Apr;15(7):1245-54. doi: 10.1002/pmic.201400286. Epub 2015 Jan 21.

PMID:
25422122
45.

The diagnostic value of interleukin-8 for the detection of bacteremia in pediatric hematopoietic stem cell recipients with febrile neutropenia.

Miedema KG, Vermont CL, Ball LM, de Bont ES, Kamps WA, van Tol MJ, Jol-van der Zijde CM, Tissing WJ.

Transplantation. 2014 Oct 27;98(8):e80-1. doi: 10.1097/TP.0000000000000434. No abstract available.

PMID:
25318571
46.

Prostaglandin E2 promotes MYCN non-amplified neuroblastoma cell survival via β-catenin stabilization.

Jansen SR, Holman R, Hedemann I, Frankes E, Elzinga CR, Timens W, Gosens R, de Bont ES, Schmidt M.

J Cell Mol Med. 2015 Jan;19(1):210-26. doi: 10.1111/jcmm.12418. Epub 2014 Sep 30.

47.

Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse.

Bachas C, Schuurhuis GJ, Reinhardt D, Creutzig U, Kwidama ZJ, Zwaan CM, van den Heuvel-Eibrink MM, De Bont ES, Elitzur S, Rizzari C, de Haas V, Zimmermann M, Cloos J, Kaspers GJ.

Br J Haematol. 2014 Sep;166(6):902-10. doi: 10.1111/bjh.12989. Epub 2014 Jun 25.

PMID:
24962064
48.

Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria.

Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, Heymans MW, Warmuth-Metz M, Hargrave D, van der Hoeven EJ, Gidding CE, de Bont ES, Eshghi OS, Reddingius R, Peeters CM, Schouten-van Meeteren AY, Gooskens RH, Granzen B, Paardekooper GM, Janssens GO, Noske DP, Barkhof F, Kramm CM, Vandertop WP, Kaspers GJ, van Vuurden DG.

Neuro Oncol. 2015 Jan;17(1):160-6. doi: 10.1093/neuonc/nou104. Epub 2014 Jun 5.

49.

Finding the right balance: An evaluation of the adequacy of energy and protein intake in childhood cancer patients.

Brinksma A, Roodbol PF, Sulkers E, de Bont ES, Burgerhof JG, Tamminga RY, Jager-Wittenaar H, Tissing WJ.

Clin Nutr. 2015 Apr;34(2):284-90. doi: 10.1016/j.clnu.2014.04.008. Epub 2014 Apr 18.

PMID:
24792686
50.

DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia.

van der Sligte NE, Krumbholz M, Pastorczak A, Scheijen B, Tauer JT, Nowasz C, Sonneveld E, de Bock GH, Meeuwsen-de Boer TG, van Reijmersdal S, Kuiper RP, Bradtke J, Metzler M, Suttorp M, de Bont ES, van Leeuwen FN.

Br J Haematol. 2014 Jul;166(2):250-3. doi: 10.1111/bjh.12850. Epub 2014 Mar 27. Erratum in: Br J Haematol. 2014 Nov;167(4):584.

PMID:
24673583

Supplemental Content

Loading ...
Support Center